Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase - Publikation - Autoren - KSSG Forschungsdatenbank

Publikation

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Wissenschaftlicher Artikel/Review - 27.06.2014

Schiff Michael H, von Kempis Johannes, Goldblum Ronald, Tesser John R, Müller Rüdiger

Schiff, Michael H

von Kempis, Johannes

Rheumatologie · Dept. I

Goldblum, Ronald

Tesser, John R

Müller, Rüdiger